KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medpace Holdings (MEDP) Non-Current Deffered Revenue: 2017-2018

Historic Non-Current Deffered Revenue for Medpace Holdings (MEDP) over the last 2 years, with Sep 2018 value amounting to $4.0 million.

  • Medpace Holdings' Non-Current Deffered Revenue fell 81.14% to $4.0 million in Q3 2018 from the same period last year, while for Sep 2018 it was $4.0 million, marking a year-over-year decrease of 81.14%. This contributed to the annual value of $11.5 million for FY2017, which is N/A change from last year.
  • According to the latest figures from Q3 2018, Medpace Holdings' Non-Current Deffered Revenue is $4.0 million, which was down 64.26% from $11.1 million recorded in Q2 2018.
  • Medpace Holdings' 5-year Non-Current Deffered Revenue high stood at $21.4 million for Q2 2017, and its period low was $4.0 million during Q3 2018.
  • Its 2-year average for Non-Current Deffered Revenue is $13.4 million, with a median of $11.4 million in 2017.
  • Data for Medpace Holdings' Non-Current Deffered Revenue shows a maximum YoY plummeted of 81.14% (in 2018) over the last 5 years.
  • Over the past 2 years, Medpace Holdings' Non-Current Deffered Revenue (Quarterly) stood at $11.5 million in 2017, then tumbled by 81.14% to $4.0 million in 2018.
  • Its Non-Current Deffered Revenue stands at $4.0 million for Q3 2018, versus $11.1 million for Q2 2018 and $11.3 million for Q1 2018.